Communiqués Formycon AG

Actions

FYB

DE000A1EWVY8

Marché Fermé - Xetra Autres places de cotation 17:36:24 16/07/2024			Après clotûre 18:50:31
53,9 ^EUR	-0,55 %		54,15	+0,46 %

01/07	La FDA américaine approuve le biosimilaire de Formycon pour le traitement de maladies graves de la rétine	MT
18/06	Borse Frankfurt-News : Beaucoup de gagnants et beaucoup de perdants (petites valeurs)	DP

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)	01/07	EQ
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)	28/06	EQ
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation	20/06	AQ
Formycon reports on the results of the Annual General Meeting	13/06	EQ
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda	13/06	EQ
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06	AQ
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	16/05	AQ
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region	15/05	EQ
Formycon reports on successful operating business and financial figures for the first quarter of 2024	08/05	EQ
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich	07/05	EQ
Formycon hosts conference call on the results of the first quarter 2024	02/05	EQ
DD: Formycon AG: Dr. Marc Mikulcik, buy	29/04	EQ
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance	25/04	EQ
DD: Formycon AG: Dr. Stefan Glombitza, buy	24/04	EQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22/04	AQ
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024	22/04	EQ
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	12/04	EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	12/04	EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	11/04	EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	03/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Formycon AG : Marché en croissance exponentielle, concurrence féroce

Le 19 septembre 2023 à 10:29